Guselkumab in Crohn's disease: the IL-23 race continues
- PMID: 38104570
- DOI: 10.1016/S2468-1253(23)00356-4
Guselkumab in Crohn's disease: the IL-23 race continues
Conflict of interest statement
MF declares consulting or lecture fees from AbbVie, Amgen, Arena, Biogen, Celtrion, CTMA, Galapagos, Janssen, MSD, Pfizer, Takeda, Tillotts, MSD, Gilead, Fresenius, Celgene, Sandoz, and Ferring. AB declares consulting fees from AbbVie, Amgen, Arena, Biogen, Celtrion, CTMA, Fresenius-Kabi, Galapagos, Janssen, MSD, Nexbiome, Pfizer, Roche, Takeda and Tillotts; lecture fees from AbbVie, Amgen, Biogen, Fresenius-Kabi Galapagos, Janssen, Mayoli-Spindler, MSD, Norgine, Pfizer, Roche, Takeda, Tillotts, and Vifor Pharma; and research grants from AbbVie, Celltrion, Janssen, Lilly, Pfizer, and Takeda.
Comment on
-
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.Lancet Gastroenterol Hepatol. 2024 Feb;9(2):133-146. doi: 10.1016/S2468-1253(23)00318-7. Epub 2023 Dec 14. Lancet Gastroenterol Hepatol. 2024. PMID: 38104569 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
